See more : SM Entertainment Co., Ltd. (041510.KQ) Income Statement Analysis – Financial Results
Complete financial analysis of Exagen Inc. (XGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Exagen Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Sonic Interfreight Public Company Limited (SONIC.BK) Income Statement Analysis – Financial Results
- Zosano Pharma Corporation (ZSAN) Income Statement Analysis – Financial Results
- Misitano & Stracuzzi S.p.A. (MS.MI) Income Statement Analysis – Financial Results
- Aena S.M.E., S.A. (AENA.MC) Income Statement Analysis – Financial Results
- Haichang Ocean Park Holdings Ltd. (2255.HK) Income Statement Analysis – Financial Results
Exagen Inc. (XGN)
About Exagen Inc.
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 52.55M | 45.56M | 48.30M | 41.98M | 40.39M | 32.44M | 26.81M | 17.95M | 11.66M | 3.06M | 926.00K |
| Cost of Revenue | 23.09M | 24.21M | 20.59M | 16.56M | 18.81M | 15.38M | 14.14M | 9.53M | 6.89M | 2.83M | 1.97M |
| Gross Profit | 29.46M | 21.35M | 27.71M | 25.42M | 21.58M | 17.06M | 12.67M | 8.41M | 4.78M | 225.00K | -1.05M |
| Gross Profit Ratio | 56.06% | 46.86% | 57.37% | 60.55% | 53.43% | 52.59% | 47.26% | 46.88% | 40.97% | 7.36% | -113.17% |
| Research & Development | 4.87M | 9.88M | 7.24M | 3.57M | 2.18M | 2.13M | 1.55M | 1.37M | 1.29M | 897.00K | 1.06M |
| General & Administrative | 45.93M | 49.02M | 42.84M | 35.73M | 27.10M | 18.28M | 17.52M | 15.91M | 13.97M | 6.56M | 4.86M |
| Selling & Marketing | 1.50M | 3.00M | 1.70M | 1.30M | 1.60M | 1.40M | 1.30M | 1.50M | 1.10M | 429.00K | 294.00K |
| SG&A | 47.43M | 52.02M | 44.54M | 37.03M | 28.70M | 19.68M | 18.82M | 17.41M | 15.07M | 6.99M | 5.15M |
| Other Expenses | 0.00 | 5.51M | 16.00K | 984.00K | 510.00K | 141.00K | 186.00K | 1.22M | -497.00K | -83.00K | 7.00K |
| Operating Expenses | 52.29M | 61.89M | 51.78M | 40.60M | 30.88M | 21.94M | 20.56M | 19.07M | 16.57M | 8.10M | 6.42M |
| Cost & Expenses | 75.39M | 86.11M | 72.37M | 57.16M | 49.69M | 37.32M | 34.69M | 28.60M | 23.46M | 10.93M | 8.39M |
| Interest Income | 1.52M | 830.00K | 16.00K | 2.28M | 2.98M | 112.00K | 45.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.34M | 2.45M | 2.63M | 2.57M | 3.49M | 2.87M | 2.95M | 4.50M | 2.94M | 941.00K | 463.00K |
| Depreciation & Amortization | 2.17M | 2.11M | 948.00K | 546.00K | 591.00K | 731.00K | 670.00K | 879.00K | 558.00K | 455.00K | 398.00K |
| EBITDA | -19.15M | -43.11M | -23.10M | -13.66M | -7.93M | -4.36M | -22.56M | -13.55M | -11.50M | -12.06M | -6.42M |
| EBITDA Ratio | -36.45% | -87.17% | -49.80% | -33.83% | -21.76% | -12.44% | -26.75% | -47.68% | -100.61% | -245.73% | -762.53% |
| Operating Income | -22.84M | -40.55M | -24.07M | -15.19M | -9.30M | -4.88M | -7.84M | -10.39M | -11.56M | -9.14M | -6.83M |
| Operating Income Ratio | -43.46% | -88.99% | -49.83% | -36.18% | -23.02% | -15.04% | -29.23% | -57.88% | -99.08% | -299.31% | -737.15% |
| Total Other Income/Expenses | -819.00K | -1.62M | -2.61M | -1.58M | -2.71M | -3.07M | -18.34M | -8.54M | -3.44M | -4.31M | 184.00K |
| Income Before Tax | -23.66M | -47.67M | -26.68M | -16.77M | -12.01M | -7.95M | -26.18M | -18.93M | -14.99M | -13.45M | -7.28M |
| Income Before Tax Ratio | -45.02% | -104.62% | -55.23% | -39.94% | -29.74% | -24.52% | -97.66% | -105.48% | -128.56% | -440.39% | -786.39% |
| Income Tax Expense | 33.00K | -282.00K | 175.00K | -79.00K | 25.00K | 58.00K | -549.00K | 253.00K | -13.00K | 42.00K | 42.00K |
| Net Income | -23.69M | -47.39M | -26.85M | -16.69M | -12.04M | -8.01M | -25.63M | -19.18M | -14.98M | -13.50M | -7.32M |
| Net Income Ratio | -45.08% | -104.00% | -55.59% | -39.75% | -29.81% | -24.70% | -95.61% | -106.89% | -128.45% | -441.77% | -790.93% |
| EPS | -1.34 | -2.77 | -1.68 | -1.32 | -0.96 | -127.16 | -406.81 | -305.48 | -265.79 | -251.43 | -206.86 |
| EPS Diluted | -1.34 | -2.77 | -1.68 | -1.32 | -0.96 | -127.16 | -406.81 | -305.48 | -265.79 | -251.43 | -206.86 |
| Weighted Avg Shares Out | 17.68M | 17.08M | 15.97M | 12.65M | 12.56M | 63.01K | 63.01K | 62.80K | 56.36K | 53.68K | 35.41K |
| Weighted Avg Shares Out (Dil) | 17.68M | 17.08M | 15.97M | 12.65M | 12.56M | 63.01K | 63.01K | 62.80K | 56.36K | 53.68K | 35.41K |
Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers
Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023
Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting
Exagen Inc. to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
Exagen Inc. (XGN) Q2 2023 Earnings Call Transcript
Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates
Exagen Inc. Reports Strong Second Quarter 2023 Results
Exagen Inc. to Participate in the Canaccord Genuity 43rd Annual Growth Conference
Exagen to Announce Second Quarter 2023 Financial Results on August 7, 2023
Exagen Inc. Appoints Paul Kim to Board of Directors
Source: https://incomestatements.info
Category: Stock Reports
What were Exagen Inc.’s revenue and net loss in Q3 2024?
Total revenue of $12.5 million in the third quarter of 2024 included the net negative impact of $1.2 million in one-time adjustments. Prior to these adjustments, revenue was in line with expectations.
What is Exagen’s adjusted EBITDA loss for the first three quarters of 2024?
Adjusted EBITDA loss through the first three quarters of 2024 was $7.6 million compared to a $13.2 million loss through the first three quarters of 2023. As of September 30, 2024, cash and cash equivalents were $22.0 million and our accounts receivable balance was $9.4 million.